APP and Alzheimer disease: The main findings of this study are as follows: (1) In both the 3xTG AD model and the APP/PS1/Tau AD model, the signal enhancement after injection of our developed contrast agent was observed from 16 weeks of age, confirming the potential for early diagnosis of AD.